Table 1.
Characteristics of Participants at Women's Interagency Human Immunodeficiency Virus Study Entry and at Last Visit
| Variable | WIHS Entry (n = 575) | Last Visit (n = 575) |
|---|---|---|
| Age, y, mean (SD) | 40 (6) | 51 (7) |
| Race/ethnicity | ||
| White, non-Hispanic | 16% (94) | |
| African American, non-Hispanic | 63% (363) | |
| Hispanic | 19% (108) | |
| HCV genotype 1 | 88% (418) | |
| HCV VL, log IU/mL, mean (SD) | 6.1 (0.91) | 6.3 (0.81) |
| CD4 count, cells/µL, median (IQR) | 375 (218–569) | 330 (109–583) |
| HIV VL, log IU/mL, mean (SD) | 4.1 (1.1) | 3.1 (1.62) |
| % HIV undetectable | 7% (41) | 33% (189) |
| ART use | 6% (32) | 63% (360) |
| FIB-4 score, median (IQR) | 1.3 (0.9–1.8) | 2.1 (1.4–3.8) |
| BMI, kg/m2, mean (SD) | 26 (6) | 26 (7) |
| Hypertension | 30% (171) | 49% (283) |
| Diabetes | 18% (105) | 18% (105) |
| eGFR, mL/min/1.73 m2, median (IQR) | 88 (73–102) | 83 (57–101) |
| Current cigarette use | 80% (460) | 66% (381) |
| Current intravenous drug use | 23% (130) | 8% (48) |
| Alcohol use, drinks/wk, median (IQR) | 0.5 (0–4) | 0 (0–1) |
| Heavy alcohol use (>7 drinks/wk) | 19% (106) | 9% (53) |
Data are presented as % (No.) unless otherwise indicated.
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; eGFR, estimated glomerular filtration rate; FIB-4, fibrosis 4; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IQR, interquartile range; SD, standard deviation; VL, viral load; WIHS, Women's Interagency HIV Study.